Methodist Health System COVID-19 Patient Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Crystee Cooper, DHEd
- Phone Number: 214-947-1285
- Email: clinicalresearch@mhd.com
Study Contact Backup
- Name: Zaid Haddadin, MS
- Phone Number: 214-947-4604
- Email: clinicalresearch@mhd.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Clinical Research Institute Methodist Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient tested positive for COVID-19 (SARS-CoV-2)
- Patient sought care for COVID-19 at a MHS facility
- Aged 18 years or older
Exclusion Criteria:
- Patient that do not have COVID-19
- Non-confirmed COVID-19 patients
- Aged 17 years or younger
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COVID-19 Cohort
Patients treated at MHS facilites for COVID-19
|
Patients treated for COVID-19
|
|
Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study
30 Day Mortality after surgery in patients with COVID19 infection who undergo elective bariatric, hepato-biliary and colorectal surgery.
|
Patients treated for COVID-19
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Characteristics
Time Frame: June 2020 - Dec 2025
|
Patient characteristics
|
June 2020 - Dec 2025
|
|
Treatment Measures and Intervention strategies
Time Frame: June 2020 - Dec 2025
|
Treatment measures and intervention strategies
|
June 2020 - Dec 2025
|
|
Clinical and survival outcomes
Time Frame: June 2020 - Dec 2025
|
Clinical and survival outcomes
|
June 2020 - Dec 2025
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Crystee Cooper, DHEd, Methodist Health System
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 024.CRI.2020.A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT06768697Not yet recruiting
-
NCT07110714RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)
-
NCT07552779RecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019)
-
NCT07445971RecruitingCOVID -19 | COVID-19 (Prevention)
-
NCT06156176RecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID Condition
-
NCT06294756CompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome
-
NCT05839236Active, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated Stroke
-
NCT07397130CompletedPost COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID Syndrome Long Covid
Clinical Trials on Treatment for COVID-19
-
NCT05655546TerminatedImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsHIV Infections | Lymphoma | Leukemia | Cancer | Multiple Myeloma | Immunosuppression | Immunodeficiency | Transplant | Graft Versus Host Disease | Age-Related Immunodeficiency
-
NCT05474157TerminatedCovid19 | Sarcopenia | Intensive Care Unit Acquired Weakness
-
NCT05216562Recruiting
-
NCT04479137CompletedCovid-19 | Risk Factor, Mortality
-
NCT05217862CompletedCOVID-19 | Cataract Surgery
-
NCT04642014TerminatedCOVID-19 Convalescent Plasma Treatment
-
NCT05278468Completed
-
NCT04575545Unknown
-
NCT04462393Active, not recruitingCOVID-19 | Critical Illness
-
NCT04432922Completed